Literature DB >> 19169813

HU210-induced downregulation in cannabinoid CB1 receptor binding strongly correlates with body weight loss in the adult rat.

Victoria S Dalton1, Hongqin Wang, Katerina Zavitsanou.   

Abstract

In vitro autoradiography was used to examine changes in cannabinoid CB1 receptors (targeted with [(3)H] CP55,940) in rats treated with the potent cannabinoid agonist HU210. Animals were administered with HU210 (25, 50, 100 microg/kg) for 4 or 14 days or received a single 100 microg/kg injection of HU210 and sacrificed 24 h later. The acute dose resulted in a decrease in binding in the caudate putamen and hippocampus. A dose dependent, region-specific reduction (P < 0.0001) in [(3)H] CP55,940 binding was seen in all brain regions examined after 4 and 14 days treatment. A decrease in body weight was recorded during the first 4 days of treatment but after this animals began to gain weight. Correlations (0.865 < r < 0.659, P < 0.0001) between body weight on day four and CB1 receptor binding were found in all brain regions examined suggesting that downregulation of CB1 receptors may contribute to the induction of tolerance to body weight loss induced by HU210.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19169813     DOI: 10.1007/s11064-009-9914-y

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  60 in total

1.  Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry.

Authors:  P Mailleux; J J Vanderhaeghen
Journal:  Neuroscience       Date:  1992       Impact factor: 3.590

Review 2.  The adverse effects of cannabinoids: implications for use of medical marijuana.

Authors:  Louisa Degenhardt; Wayne D Hall
Journal:  CMAJ       Date:  2008-06-17       Impact factor: 8.262

3.  Cannabinoid receptor and WIN-55,212-2-stimulated [35S]GTPgammaS binding and cannabinoid receptor mRNA levels in several brain structures of adult male rats chronically exposed to R-methanandamide.

Authors:  J Romero; F Berrendero; L García-Gil; S Y Lin; A Makriyannis; J A Ramos; J J Fernández-Ruiz
Journal:  Neurochem Int       Date:  1999-06       Impact factor: 3.921

4.  Stereochemical effects of 11-OH-delta 8-tetrahydrocannabinol-dimethylheptyl to inhibit adenylate cyclase and bind to the cannabinoid receptor.

Authors:  A C Howlett; T M Champion; G H Wilken; R Mechoulam
Journal:  Neuropharmacology       Date:  1990-02       Impact factor: 5.250

5.  Chronic treatment with a synthetic cannabinoid CP-55,940 alters G-protein expression in the rat central nervous system.

Authors:  T Rubino; G Patrini; M Parenti; P Massi; D Parolaro
Journal:  Brain Res Mol Brain Res       Date:  1997-03

6.  Characterization of the hypothermic effect of the synthetic cannabinoid HU-210 in the rat. Relation to the adrenergic system and endogenous pyrogens.

Authors:  H Ovadia; A Wohlman; R Mechoulam; J Weidenfeld
Journal:  Neuropharmacology       Date:  1995-02       Impact factor: 5.250

7.  Cannabis use and the risk of developing a psychotic disorder.

Authors:  Wayne Hall; Louisa Degenhardt
Journal:  World Psychiatry       Date:  2008       Impact factor: 49.548

8.  Neurotransmitter receptor analysis in transgenic mouse models.

Authors:  Caroline L Benn; Laurie A Farrell; Jang-Ho J Cha
Journal:  Methods Mol Biol       Date:  2004

9.  Enantiomeric cannabinoids: stereospecificity of psychotropic activity.

Authors:  R Mechoulam; J J Feigenbaum; N Lander; M Segal; T U Järbe; A J Hiltunen; P Consroe
Journal:  Experientia       Date:  1988-09-15

Review 10.  The endogenous cannabinoid system and the basal ganglia. biochemical, pharmacological, and therapeutic aspects.

Authors:  Julián Romero; Isabel Lastres-Becker; Rosario de Miguel; Fernando Berrendero; José A Ramos; Javier Fernández-Ruiz
Journal:  Pharmacol Ther       Date:  2002-08       Impact factor: 12.310

View more
  8 in total

1.  Repeated administration of a synthetic cannabinoid receptor agonist differentially affects cortical and accumbal neuronal morphology in adolescent and adult rats.

Authors:  A F Carvalho; B A S Reyes; F Ramalhosa; N Sousa; E J Van Bockstaele
Journal:  Brain Struct Funct       Date:  2014-10-28       Impact factor: 3.270

2.  Acute cannabinoid receptor type 1 (CB1R) modulation influences insulin sensitivity by an effect outside the central nervous system in mice.

Authors:  D Song; R H J Bandsma; C Xiao; L Xi; W Shao; T Jin; G F Lewis
Journal:  Diabetologia       Date:  2011-02-22       Impact factor: 10.122

3.  Use of new and uncommon synthetic psychoactive drugs among a nationally representative sample in the United States, 2005-2017.

Authors:  Joseph J Palamar; Austin Le
Journal:  Hum Psychopharmacol       Date:  2019-03-06       Impact factor: 1.672

4.  Paranoid schizophrenia is characterized by increased CB1 receptor binding in the dorsolateral prefrontal cortex.

Authors:  Victoria S Dalton; Leonora E Long; Cyndi Shannon Weickert; Katerina Zavitsanou
Journal:  Neuropsychopharmacology       Date:  2011-04-06       Impact factor: 7.853

5.  Synthetic Cannabinoid Use Among High School Seniors.

Authors:  Joseph J Palamar; Monica J Barratt; Leigh Coney; Silvia S Martins
Journal:  Pediatrics       Date:  2017-09-11       Impact factor: 7.124

Review 6.  Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications.

Authors:  Marisol S Castaneto; David A Gorelick; Nathalie A Desrosiers; Rebecca L Hartman; Sandrine Pirard; Marilyn A Huestis
Journal:  Drug Alcohol Depend       Date:  2014-08-18       Impact factor: 4.492

7.  Comparison of Cannabinoid CB(1) Receptor Binding in Adolescent and Adult Rats: A Positron Emission Tomography Study Using [F]MK-9470.

Authors:  Mathieu Verdurand; Vu Nguyen; Daniela Stark; David Zahra; Marie-Claude Gregoire; Ivan Greguric; Katerina Zavitsanou
Journal:  Int J Mol Imaging       Date:  2011-12-11

Review 8.  Targeting the Endocannabinoid CB1 Receptor to Treat Body Weight Disorders: A Preclinical and Clinical Review of the Therapeutic Potential of Past and Present CB1 Drugs.

Authors:  Thomas Murphy; Bernard Le Foll
Journal:  Biomolecules       Date:  2020-06-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.